Sjögren's disease & overlap diseases
The impact of Sjögren's disease on ovarian reserve: a systematic review and meta-analysis
Pooled result · Serum AMHResult — go to the resultSMD −0.73 95% CI −1.09 to −0.37Authors' conclusion
Although limited data prevent definitive confirmation of how SjD affects ovarian reserve, this preliminary study strongly underscores the critical need for increased clinical awareness of the condition in reproductive medicine.
Study context
- Population
- Reproductive-age women with Sjögren's disease (SjD) and age-matched disease-free controls; 5 databases searched through December 1, 2025
- Participants
- 410 women4 observational studies
- Comparison
- Reproductive-age women with SjD vs age-matched disease-free controls
- Outcome
- Ovarian reserve: serum AMH, FSH, AFC or OV
Methodological detailsPRISMA 2020, Newcastle-Ottawa Scale and AHRQ quality assessment, standardised mean differences (SMDs) with 95% confidence intervals (CIs)
- PRISMA 2020
- Newcastle-Ottawa Scale and AHRQ quality assessment
- SMDs with 95% CIs
Pooled result
Serum AMH
SMD
−0.73
95% CI −1.09 to −0.37
P < 0.0001
SjDvs Controls
SMD −0.73 (95% CI −1.09 to −0.37); P < 0.0001
As reported in the abstract
Further pooled results
| Outcome | SMD (95% CI) | P value | |
|---|---|---|---|
| Serum FSH levels | 0.35 (0.14–0.57) | P < 0.001 | |
| −0.500.51Difference (linear scale) |
- Serum follicle-stimulating hormone (FSH) levels: statistical significance remained sensitive to the inclusion of specific studies
Serum FSH levels
- Trend toward higher FSH levels
Antral follicle count (AFC)
- No significant difference
Ovarian volume (OV)
- No significant difference
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The impact of Sjögren's disease on ovarian reserve: a systematic review and meta-analysis. Clin Exp Rheumatol. Published 5 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →